Is There Life Left In Laquinimod? Teva Bows Out, But Active Biotech Interested In Brain Atrophy

The extensively evaluated immunomodulator candidate laquinimod may still have potential in the treatment of neurodegenerative diseases, says Sweden's Active Biotech, despite previous disappointing clinical trials in multiple sclerosis and Huntington's disease conducted by Teva.